Loading company…
Wuhan Kangfude develops oral enzyme and microbiome-based medicines.
Based in Wuhan, China, Wuhan Kangfude researches oral enzyme and microecological drugs. Its products include oxalate decarboxylase TRA16, which degrades oxalate in food, and candidates for hyperuricemia and gout. Founded in 2010, the company listed on the National Equities Exchange and Quotations System in 2015 under stock code 832036.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in